Posted in C - Clovis Oncology, C - Ethical Oncology Science, C – Advenchen Laboratories, C – Servier, License Agreements, MUT: PDGF, MUT: VEGF, SM - Lucitanib, X - Oncology, X – Cancer: Breast, X – Cancer: Lung, X – Cancer: Renal, X – Cancer: Thyroid, XX - CO, XX - France, XX - Italy, Y - 2013
November 2013, Clovis Oncology ($CLVS @ClovisOncology) acquired Ethical Oncology Science, S.p.A. (“EOS”) (known as Clovis Oncology Italy S.r.l., or “COI”) through which the rights to lucitanib were obtained.
2008, EOS had in-licensed exclusive development and commercial rights to lucitanib on a global basis, excluding China, from Advenchen Laboratories.
September 2012, EOS entered into a collaboration and license agreement with Servier, whereby EOS sublicensed to Servier exclusive rights to develop and commercialize lucitanib in all countries outside of the U.S., Japan and China.
Clovis holds exclusive rights for lucitanib in the U.S. and Japan, and is collaborating with Servier on the global clinical development of lucitanib outside of China.
Upfront Payment 1.0 Clovis $200MM to EOS, which included $190MM in $CLVS common stock (3,713,731 shares) and $10MM in cash.
Upfront Payment 2.0 In exchange for the rights granted to Servier, EOS received an upfront payment of €45.MM
Milestone 1.0 Clovis is entitled to receive additional payments on the achievement of specified development, regulatory and commercial milestones up to €100.0 MM in aggregate, of which €10.0MM was received in 1Q14
Milestone 2.0 Clovis will pay an additional $65MM to EOS upon the initial approval of lucitanib
Milestone 2.1 Clovis will also pay EOS up to an additional €115MM (~$155MM) upon certain milestones pursuant to the Servier license agreement